RETA Stock - Reata Pharmaceuticals, Inc.
Unlock GoAI Insights for RETA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $2.22M | $11.49M | $9.02M | $26.52M | $53.59M |
| Gross Profit | $2.22M | $11.49M | $9.02M | $-97,881,000 | $53.59M |
| Gross Margin | 100.0% | 100.0% | 100.0% | -369.1% | 100.0% |
| Operating Income | $-270,155,000 | $-244,708,000 | $-226,325,000 | $-285,220,000 | $-76,878,000 |
| Net Income | $-311,901,000 | $-297,386,000 | $-247,752,000 | $-290,170,000 | $-80,546,000 |
| Net Margin | -14075.0% | -2588.2% | -2747.0% | -1094.3% | -150.3% |
| EPS | $-8.59 | $-8.19 | $-7.35 | $-9.54 | $-2.91 |
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 6th 2023 | TD Cowen | Initiation | Outperform | $140 |
| June 12th 2023 | SVB Securities | Upgrade | Outperform | $115← $80 |
| October 19th 2022 | Guggenheim | Initiation | Buy | $75 |
Earnings History & Surprises
RETAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Aug 5, 2024 | — | — | — | — |
Q2 2024 | May 8, 2024 | — | — | — | — |
Q1 2024 | Feb 22, 2024 | — | — | — | — |
Q4 2023 | Nov 14, 2023 | $-2.15 | — | — | — |
Q3 2023 | Aug 8, 2023 | $2.88 | $2.32 | -19.4% | ✗ MISS |
Q2 2023 | May 10, 2023 | $2.34 | $3.14 | +34.2% | ✓ BEAT |
Q1 2023 | Feb 24, 2023 | $-2.21 | $-2.33 | -5.4% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $2.35 | $2.16 | -8.1% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $1.90 | $2.02 | +6.3% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $2.26 | $2.03 | -10.2% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $2.31 | $2.35 | +1.7% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $2.32 | $1.97 | -15.1% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $2.13 | $2.00 | -6.1% | ✗ MISS |
Q2 2021 | May 6, 2021 | $2.18 | $1.86 | -14.7% | ✗ MISS |
Q1 2021 | Mar 1, 2021 | $2.14 | $1.90 | -11.2% | ✗ MISS |
Q4 2020 | Nov 9, 2020 | $2.10 | $1.94 | -7.6% | ✗ MISS |
Q3 2020 | Aug 10, 2020 | $2.22 | $2.03 | -8.6% | ✗ MISS |
Q2 2020 | May 11, 2020 | $1.97 | $0.89 | -54.8% | ✗ MISS |
Q1 2020 | Feb 19, 2020 | $6.15 | $5.91 | -3.9% | ✗ MISS |
Q4 2019 | Nov 12, 2019 | $1.25 | $1.32 | +5.6% | ✓ BEAT |
Latest News
Frequently Asked Questions about RETA
What is RETA's current stock price?
What is the analyst price target for RETA?
What sector is Reata Pharmaceuticals, Inc. in?
What is RETA's market cap?
Does RETA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to RETA for comparison